Global Coronary Artery Bypass Grafts (CABG) Market Strategic Research Report

Scope of the Report

The global Coronary Artery Bypass Grafts (CABG) market size is predicted to grow from US$ 153 million in 2025 to US$ 216 million in 2032; it is expected to grow at a CAGR of 5.1% from 2026 to 2032.

Coronary artery bypass surgery, also known as coronary artery bypass graft (CABG) surgery, and colloquially heart bypass or bypass surgery, is a surgical procedure to restore normal blood flow to an obstructed coronary artery.

Coronary artery bypass grafting (CABG) is a surgical intervention to restore myocardial blood supply by creating bypass conduits—using autologous or alternative vascular grafts—around narrowed or occluded coronary arteries to preserve cardiac muscle, relieve ischemic symptoms, and reduce the risk of adverse cardiac events. As a standard of care for multivessel and complex coronary disease, CABG spans from conventional open-chest on-pump procedures to refined, less invasive techniques and supporting adjuncts. The perioperative ecosystem—graft preservation, intraoperative perfusion management, hemostasis, consumables, and postoperative rehabilitation—forms an integrated market that includes devices, disposables, pharmacologic adjuncts, and service offerings.

The sustained public-health emphasis on cardiovascular disease burden provides an enduring demand base for CABG where durable outcomes and long-term quality of life matter. Innovations in graft preservation, intraoperative blood management and alternative conduit materials, together with commercialization by listed and R&D companies, are expanding addressable product categories and creating premium commercialization opportunities for firms that can pair clinical evidence with scalable manufacturing.

Major restraints include rigid regulatory requirements, the need for long-term clinical evidence, and stringent quality controls. Novel devices and graft materials typically require extended clinical programs and regulatory interactions before adoption into standard surgical pathways; post-market safety or quality issues can materially impact compliance costs and brand trust. Supply-chain robustness, sterile manufacturing capability, and hospital budget dynamics also present tangible commercialization risks.

This report presents a comprehensive overview of the global Coronary Artery Bypass Grafts (CABG) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Saphenous Vein Grafts
• Internal Thoracic Artery Grafts
• Other

Segment by players, this report covers

• Medtronic
• Getinge Group
• LivaNova
• Terumo
• Boston Scientific
• Stryker
• Edwards Lifesciences
• Genesee Biomedical
• Karl Storz GmbH

Segment by Application

• Traditional CABG
• Nontraditional CABG

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Coronary Artery Bypass Grafts (CABG) market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Traditional CABG, Nontraditional CABG evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact